Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer

NCT07830407 · tracked via the Priya Life Science UK tracker

Sponsor

Pierian Biosciences

Phase

Observational

Started

2026-04-21

Last updated

2026-09-21

Condition(s) studied

Colorectal Cancer

Study summary

This is a prospective, non-randomized, observational, pre-clinical validation study. Pierian Biosciences is utilizing ChemoINTEL assay measured in vitro cytotoxic drug induced apoptosis and cell death in isolated fresh human tumour cells from patients with colorectal cancer (CRC) to predict a patient's tumour's sensitivity to specific chemotherapy drugs using the ChemoINTEL unified algorithm. Eligible patients will be assigned to one of three groups depending on the stage of disease :

Group 1: Patients who have colorectal cancer and are referred for adjuvant chemotherapy after MDT discussion.

Group 2: Patients with stage II colorectal cancer with high risk features not referred for adjuvant chemotherapy (at risk of relapse) Group 3: Patients with locally advanced rectal cancer who have had a complete response to chemoradiotherapy (research objective).

At least one solid tumour specimen and adjacent normal tissue will be sent to Pierian Biosciences Laboratory in Liverpool, UK along with an optional 10-20ml blood sample and The Pierian Biosciences laboratory staff will conduct the ChemoINTEL and ImmunoINTEL assays blinded to all specimen and clinical information except the tumor type (e.g. Colon Cancer or Rectal Cancer), Specimen ID, and specimen collection date and time. Results of the assay will NOT be shared with clinical sites. Samples from group 3 will be provided if patients undergo surgical resection.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria Group 1 Participants: 1. ≥18 years of age 2. Diagnosis of CRC i. Surgical resection followed by adjuvant chemotherapy ii. Biopsy followed by neoadjuvant chemo/radiotherapy and surgical resection. 3. Patients planned to receive at least 6 cycles of standard of care chemotherapy for CRC with single agent or combination of drugs listed in Table 3 following biopsy OR surgical resection 4. One solid tumor specimen is required; a total of two specimens are preferred and requested when available. Specimens will include: i. Primary solid tumor specimen (≥400 mg) ii. Adjacent normal tissue (\>400mg) 5. Patient signed Informed Consent Form Exclusion Criteria Group 1 Participants: 1. Patient has not signed an ICF to participate in a clinical investigation 2. Patient has a cancer other than advanced stage CRC 3. Patient is NOT expected to receive SOC chemotherapy, single agents or combination treatment, as listed in Table 3 4. Patients who do not have at sufficient viable cells recovered from fresh tumor dissociation available for the ChemoINTEL assay analysis of Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Capecitabine

Primary outcome measure(s)

Primary Objective — Approximately 4 weeks post chemotherapy completion
To evaluate Group 1 ChemoINTEL Assay Unified Algorithm's prediction accuracy of clinical response to chemotherapy in patients with minimal residual colorectal cancer disease detectable by ctDNA post-surgery (prior to Cycle 1 chemotherapy) using patient response assessed by ctDNA measured 4 weeks post chemotherapy completion

Trial sites (1)

Facility	City	Region	Status
Liverpool University Hospital NHS Foundation Trust	Liverpool	Merseyside	Recruiting

More Pierian Biosciences trials in the UK

ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients Recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer Active, not recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer Active, not recruiting

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07830407 on ClinicalTrials.gov ↗ ← All trials in the UK